All News

IQVIA, a health information technology and clinical research company, recently announced a new collaboration with JDRF, the world’s largest nonprofit funder of type 1 diabetes (T1D) research. Together, the companies plan to develop a real-world research platform to facilitate evidence generation for T1D via non-identified patient-level data and analytics.

The researchers noted that these results can help inform therapeutic decision making and identify opportunities to address barriers to disease-modifying drug (DMD) adherence, which not only improves clinical outcomes but also reaps benefits when it comes to health care costs.

This week, the top managed care news included states suing the Trump administration over an HHS rule on nondiscrimination; experimental vaccines show promise against COVID-19 in healthy subjects; diagnostic delays from COVID-19 may increase cancer-related deaths.

The health burden of comorbid chronic obstructive pulmonary disease (COPD) and asthma is known to be greater than when either condition exists on its own. An upcoming study shows that COPD is linked with greater all-cause mortality and greater risk of mortality in patients with coexisting asthma who also had long-term use of corticosteroids.

New CDC data outline the prevalence of 5 common underlying health conditions that exacerbate coronavirus disease 2019 (COVID-19) symptoms; the FDA announced information regarding naloxone must be included on labels for opioids and opioid use disorder medications; despite a district judge's ruling nearly a month ago, hundreds of migrant detainees are being held in detention centers in states where COVID-19 cases are surging.

Labs nationwide are struggling to meet the processing demands of surging coronavirus disease 2019 (COVID-19) tests, causing long delays; levels of antibodies against SARS-CoV-2, the virus that causes COVID-19, were found to drop dramatically across the first 3 months of infection; suspected opioid-related overdoses have more than doubled in Wisconsin amid the pandemic.

Findings from the Michael J. Fox Foundation’s (MJFF) coronavirus disease 2019 (COVID-19) survey, based on patient-reported information from Fox Insight, highlight the known adverse effects of general infections on worsening of motor and nonmotor symptoms in patients with Parkinson disease (PD). However, there still remains insufficient data on the specified risk of COVID-19 in the PD community, noted Vanessa Arnedo, vice president of Research Cohorts for MJFF, and Ethan Brown, MD, neurologist and principal investigator of the MJFF COVID-19 survey.